Multidisciplinary approach to the treatment of cardiac AA amyloidosis and aortic stenosis due to Castleman's disease: a hybrid therapy with tocilizumab and aortic valve replacement

Int J Cardiol. 2014 May 1;173(2):e9-e11. doi: 10.1016/j.ijcard.2014.03.054. Epub 2014 Mar 16.

Authors

Kohsuke Shirakawa¹, Toru Egashira², Masaki Ieda¹, Shinji Kawaguchi³, Kazuma Okamoto³, Mikihiko Kudo³, Kenji Yokoyama⁴, Hikaru Tsuruta¹, Mitsushige Murata¹, Shuji Mikami⁵, Atsushi Anzai¹, Kentaro Hayashida¹, Takashi Kohno¹, Yuichiro Maekawa¹, Motoaki Sano¹, Ryohei Yozu³, Keiichi Fukuda¹

Affiliations

¹ Department of Cardiology, Keio University School of Medicine, Japan.
² Department of Cardiology, Keio University School of Medicine, Japan. Electronic address: egashira@cpnet.med.keio.ac.jp.
³ Department of Surgery, Division of Cardiovascular Surgery, Keio University School of Medicine, Japan.
⁴ Department of Hematology, Keio University School of Medicine, Japan.
⁵ Division of Diagnostic Pathology, Keio University Hospital, Japan.

PMID: 24681024
DOI: 10.1016/j.ijcard.2014.03.054

No abstract available

Keywords: Aortic stenosis; Cardiac AA amyloidosis; Castleman's disease; Surgical aortic valve replacement; Tocilizumab.

Publication types

Case Reports
Letter

MeSH terms

Aged
Amyloidosis / diagnostic imaging
Amyloidosis / drug therapy*
Amyloidosis / etiology
Anti-Inflammatory Agents / therapeutic use
Antibodies, Monoclonal, Humanized / therapeutic use*
Aortic Valve Stenosis / diagnostic imaging
Aortic Valve Stenosis / etiology
Aortic Valve Stenosis / surgery*
Castleman Disease / complications*
Combined Modality Therapy
Female
Heart Valve Prosthesis Implantation*
Humans
Ultrasonography

Substances

Anti-Inflammatory Agents
Antibodies, Monoclonal, Humanized
tocilizumab